New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Thursday, November 12, 2026

Back to the front page

Looking Back at Another Successful Thesis

DoubleU Games raised its all-cash tender offer for DoubleDown Interactive minority holders to $16.25 per ADS from $11.25 after net cash made the earlier bid untenable.

From X

@convequity

Convequity on X

Removing Jensen Huang is a mistake for NVIDIA's board and for US geopolitical policy. At Convequity we were relatively bearish on $NVDA versus $AVGO at the October 2026 valuation, and we did not think NVDA was a clear bargain. That does not change our view that Jensen Huang is the best semiconductor leader the industry has ever had. Removing him outright, without a stronger public story justifying the move, is a mistake. Making the CFO the interim CEO while the board searches for a permanent successor is a massive mistake. No successor can match Jensen's combination of care, vision, and execution. Best case: the next CEO continues Jensen's roadmap and keeps him as a strategic advisor, letting NVDA stay on the frontier of AI chips and infrastructure software. Base case: NVDA prints several years of pretty good numbers, then fades the way Intel did. When a founder-scale leader leaves, too few people inside and outside the company take the long-term view. Wall Street and politicians reward short-term financials and political wins, not the longer-term benefits. Leadership loss does not happen overnight. It arrives years later, when the roadmap Jensen set stops being renewed and the company slips from the frontier. That would be a painful lesson for stakeholders. Without Jensen, NVDA may still ship more chips and scale, but it will not catch the best frontier competitors. It will not make the bold quick moves this moment requires—like acquiring Groq or Hugging Face to adjust to the latest compute paradigm, open-model strategy, and new business models that build moats over the longer term. The CUDA moat is already getting shaky. We agree with one WSJ comment on the news: "A truly stupid idea, shareholders should sue the board and ask for an injunction immediately from a judge." We view removing Jensen as a mistake for the board and for US geopolitical policy.

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

Top Rebound Stocks for Nov’26

Texas Pacific Land's 50% selloff reflects faded data-center expectations, while its Permian royalty business generated $498 million of 2025…

ASML ($ASML) Deep Dive

ASML monopolizes EUV lithography, a critical tool for leading-edge chips, with production capacity stretched through 2028 and customer…

BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

Intel Panther Lake Teardown

Intel’s Panther Lake puts 18A PowerVia backside power and RibbonFET GAA transistors into commercial silicon, with logic density similar to…

Updates

FGPR remains on track, PRTH's management buyout is set at $8.05, and microcap RAVE is described as cheap.

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.